Bluesphere Advisors LLC Increases Stock Position in Eli Lilly and Company $LLY

Key Points

• Bluesphere Advisors LLC has enhanced its stake in Eli Lilly and Company by 29.1%, owning 1,550 shares valued at approximately $1.21 million, indicating strong confidence in the company's future.
• Several hedge funds have also increased their positions on Eli Lilly shares, with 82.53% of the stock now owned by institutional investors, demonstrating significant institutional interest.
• Despite a positive earnings report where Eli Lilly surpassed estimates with a 37.6% year-over-year revenue increase, various analysts have adjusted their target prices, reflecting mixed sentiments in the market.

Bluesphere Advisors LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 29.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,550 shares of the company's stock after buying an additional 349 shares during the quarter. Eli Lilly and Company accounts for about 0.6% of Bluesphere Advisors LLC's holdings, making the stock its 27th biggest holding. Bluesphere Advisors LLC's holdings in Eli Lilly and Company were worth $1,209,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in LLY. Brighton Jones LLC lifted its stake in Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock worth $7,409,000 after acquiring an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC lifted its stake in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock worth $1,136,000 after acquiring an additional 40 shares during the last quarter. Douglas Lane & Associates LLC raised its holdings in Eli Lilly and Company by 5.7% during the first quarter. Douglas Lane & Associates LLC now owns 2,985 shares of the company's stock worth $2,465,000 after purchasing an additional 162 shares in the last quarter. Future Financial Wealth Managment LLC raised its holdings in Eli Lilly and Company by 3.3% during the first quarter. Future Financial Wealth Managment LLC now owns 1,578 shares of the company's stock worth $1,303,000 after purchasing an additional 50 shares in the last quarter. Finally, Baker Tilly Wealth Management LLC raised its holdings in Eli Lilly and Company by 5.9% during the first quarter. Baker Tilly Wealth Management LLC now owns 1,447 shares of the company's stock worth $1,195,000 after purchasing an additional 80 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Transactions at Eli Lilly and Company

In other news, EVP Daniel Skovronsky bought 1,000 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $634.40 per share, with a total value of $634,400.00. Following the purchase, the executive vice president owned 137,660 shares of the company's stock, valued at $87,331,504. This trade represents a 0.73% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO David A. Ricks bought 1,632 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the purchase, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. The trade was a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 4,514 shares of company stock worth $2,894,841 in the last ninety days. Company insiders own 0.13% of the company's stock.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $725.54 on Tuesday. The firm has a market capitalization of $686.69 billion, a P/E ratio of 47.42, a PEG ratio of 1.01 and a beta of 0.47. Eli Lilly and Company has a one year low of $623.78 and a one year high of $937.00. The company's fifty day moving average is $733.42 and its two-hundred day moving average is $765.98. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the previous year, the company posted $3.92 EPS. The firm's revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on LLY shares. Erste Group Bank cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Morgan Stanley reaffirmed an "overweight" rating and issued a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. Cantor Fitzgerald cut their target price on shares of Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating on the stock in a report on Wednesday, August 13th. Deutsche Bank Aktiengesellschaft cut their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Finally, Daiwa Capital Markets cut shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 target price on the stock. in a report on Sunday, August 17th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and a consensus price target of $939.61.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.